Sentir

SmartGuard technology; Predictive Low Glucose technology

Medtronic Minimed, Inc. · K251217

FDA-authorized Predetermined Change Control Plan

1 of 64 AI/SaMD1 of 10 in Clinical Chemistryauthorized 2025
Company
Medtronic Minimed, Inc.
510(k)/De Novo #
K251217
Decision date
2025-08-29
Panel
Clinical Chemistry
Pathway
510(k)
Category
AI/SaMD
PCCP type
Compatibility expansion
Monitoring commitment
Unknown

What this PCCP covers. Permits compatibility expansion to additional hardware

Browse

Other PCCPs from Medtronic Minimed, Inc.

Other Clinical Chemistry PCCPs

Want the monitoring teardown?

We read the PCCP for SmartGuard technology; Predictive Low Glucose technology, then map the post-market monitoring that its modification protocol requires, including the deployment-period evidence most teams can't reconstruct at modification time. Sentir is the independent system of record that produces it.

Book a call

Source: U.S. FDA public records (openFDA 510(k)/De Novo databases and accessdata.fda.gov). PCCP type and category are editorial classifications based on public documents, not official FDA designations.

This page is a factual summary of public FDA records. Sentir Health is not affiliated with or endorsed by the named companies or the U.S. Food and Drug Administration. Spot an error? Request a correction.